title: Experiences in intravenous urokinase treatment of 100 acute myocardial infarction patients.
abstract: From 1980 to 1990 we treated 100 cases of AMI with i.v. urokinase (UK). According to the way of management and the dosage administered all these cases were divided into three groups: first stage of small dosage, second stage of trial big dosage, and third stage of comprehensive dosage. 36 patients of the first stage were treated with small dosage, 1-20,000 U b.i.d. for 1 week. 75% of the UK-treated and only 17% of the control group obtained relief of pain. Decrease of elevated ST reaching base line was 50 vs 8%, and FDP increased in 94%. 22 patients of the second stage were undergoing trial of big dosage. They were subdivided into larger dosage (more than 800,000 U) and smaller dosage (less than 300,000 U) groups. From the larger dosage group, 2 patients showed definite sign of recanalization, but unexpectedly 2 patients died of cardiac rupture. Since the recanalization rate of larger dosage group was 42.9%, but no case showed sign of recanalization in smaller dosage group, we are of the opinion that the dose of 800,000 U is rational for patients with symptoms' onset less than 3 h. Cardiac rupture was thought to be mostly due to reperfusion injury. Thus we designed the third stage of comprehensive dosage of UK. In this stage we used different dosage of UK and different ways of administration in 52 patients, based on the different symptoms' onset, so as to bring the effect of UK in full play. The aim of using UK is chiefly fibrinolysis as well as improvement of blood viscosity.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Internal Medicine, Tongji Hospital, Tongji Medical University, Wuhan.
authors.forename: H Y
authors.initials: HY
authors.lastname: Zhao
authors.forename: H B
authors.initials: HB
authors.lastname: Li
authors.forename: L
authors.initials: L
authors.lastname: Wang
authors.forename: X H
authors.initials: XH
authors.lastname: Zheng
authors.forename: H
authors.initials: H
authors.lastname: Wu
mesh_terms: D000368:Aged; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
chemical_list: D006493:Heparin; D014568:Urokinase-Type Plasminogen Activator